Quris Earns Frost & Sullivan 2022 Europe Technology Innovation Leadership Award for AI-Powered Drug Safety Prediction
Retrieved on:
Wednesday, August 31, 2022
Machine learning, Best Practice & Research: Clinical Rheumatology, Human, Technology, SAN, Toxicity, Achievement, Solution, Frost & Sullivan, Intelligence, ML, Traffic barrier, Creativity, Leadership, Recognition, Therapy, Drug discovery, Frost, Industry, Drug development, AI, Pharmaceutical industry, Medical device, Quri (disambiguation)
SAN ANTONIO, Aug. 31, 2022 /PRNewswire/ -- Frost & Sullivan recently researched the artificial intelligence (AI)-enabled drug safety prediction technology industry and, based on its findings, recognizes Quris with the 2022 Europe Technology Innovation Leadership Award. The innovative Quris Bio-AI Clinical Prediction Platform is the first AI breakthrough to close the clinical prediction gap by effectively predicting which drug candidates will work safely in humans.
Key Points:
- Analysts found that the Quris Bio-AI Clinical Prediction Platform enhances drug development process agility, shortens discovery timelines, increases drug safety, and improves drug pipeline diversification opportunities
SAN ANTONIO, Aug. 31, 2022 /PRNewswire/ -- Frost & Sullivan recently researched the artificial intelligence (AI)-enabled drug safety prediction technology industry and, based on its findings, recognizes Quris with the 2022 Europe Technology Innovation Leadership Award. - The innovative Quris Bio-AI Clinical Prediction Platform is the first AI breakthrough to close the clinical prediction gap by effectively predicting which drug candidates will work safely in humans.
- "Quris AI Chip-on-Chip platform, unlike other AI-pharma solutions focusing on drug discovery, better indicates which drug candidates will safely work in humans.
- In addition to its drug safety prediction pharma services, Quris also has a drug pipeline and provides personalized medicine services.